Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

Michael Green, Jonathan Lowe, Manikandan Kadirvel*, Adam McMahon, Nigel Westwood, Sue Chua, Gavin Brown

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
8 Downloads (Pure)


Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [124I] for a proof of concept study to assess the diagnostic accuracy of [124I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [124I]sodium iodide and meta-trimethylsilylbenzylguanidine. [124I]mIBG was produced in 62–70 % radioiodide incorporation yield from [124I]sodium iodide. The average amount of formulated [124I]mIBG was 359 MBq (range 344–389 MBq) with an average specific radioactivity of 4.1 TBq μmol−1 (range 1.8–5.9 TBq μmol−1) at end of synthesis.

Original languageEnglish
Pages (from-to)727-732
Number of pages6
JournalJournal of Radioanalytical and Nuclear Chemistry
Issue number1
Early online date24 Oct 2016
Publication statusPublished - Jan 2017

Bibliographical note

Funding Information:
This work was supported by Cancer Research UK Grant A15107 and Rising Tide. The author (SC) acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) and EPSRC in association with the MRC and DoH (England).

Publisher Copyright:
© 2016, The Author(s).


  • Meta-iodobenzylguanidine
  • mIBG
  • Neuroblastoma
  • Positron emission tomography
  • Radiochemistry
  • [I]

ASJC Scopus subject areas

  • Analytical Chemistry
  • Nuclear Energy and Engineering
  • Radiology Nuclear Medicine and imaging
  • Pollution
  • Spectroscopy
  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis


Dive into the research topics of 'Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma'. Together they form a unique fingerprint.

Cite this